Immune genes are associated with human glioblastoma pathology and patient survivalReportar como inadecuado




Immune genes are associated with human glioblastoma pathology and patient survival - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Medical Genomics

, 5:41

First Online: 14 September 2012Received: 02 February 2012Accepted: 06 August 2012

Abstract

BackgroundGlioblastoma GBM is the most common and lethal primary brain tumor in adults. Several recent transcriptomic studies in GBM have identified different signatures involving immune genes associated with GBM pathology, overall survival OS or response to treatment.

MethodsIn order to clarify the immune signatures found in GBM, we performed a co-expression network analysis that grouped 791 immune-associated genes IA genes in large clusters using a combined dataset of 161 GBM specimens from published databases. We next studied IA genes associated with patient survival using 3 different statistical methods. We then developed a 6-IA gene risk predictor which stratified patients into two groups with statistically significantly different survivals. We validated this risk predictor on two other Affymetrix data series, on a local Agilent data series, and using RT-Q-PCR on a local series of GBM patients treated by standard chemo-radiation therapy.

ResultsThe co-expression network analysis of the immune genes disclosed 6 powerful modules identifying innate immune system and natural killer cells, myeloid cells and cytokine signatures. Two of these modules were significantly enriched in genes associated with OS. We also found 108 IA genes linked to the immune system significantly associated with OS in GBM patients. The 6-IA gene risk predictor successfully distinguished two groups of GBM patients with significantly different survival OS low risk: 22.3 months versus high risk: 7.3 months; p < 0.001. Patients with significantly different OS could even be identified among those with known good prognosis methylated MGMT promoter-bearing tumor using Agilent OS 25 versus 8.1 months; p < 0.01 and RT-PCR OS 21.8 versus 13.9 months; p < 0.05 technologies. Interestingly, the 6-IA gene risk could also distinguish proneural GBM subtypes.

ConclusionsThis study demonstrates the immune signatures found in previous GBM genomic analyses and suggests the involvement of immune cells in GBM biology. The robust 6-IA gene risk predictor should be helpful in establishing prognosis in GBM patients, in particular in those with a proneural GBM subtype, and even in the well-known good prognosis group of patients with methylated MGMT promoter-bearing tumors.

KeywordsGlioblastoma Immune system Survival Electronic supplementary materialThe online version of this article doi:10.1186-1755-8794-5-41 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor:

Fuente: https://link.springer.com/







Documentos relacionados